Abstract
Hypercalcemia is a relatively frequent alteration, mostly associated to primary hyperparathyroidism (PHPT) and malignancy-associated hypercalcemia (MAH). Treatment first includes rehydration and loop diuretics, as general measures. Bisphosphonates are considered the drugs of choice due to their long-term management. Calcitonin is preferable in the short-term control of severe hypercalcemia. The antireabsorptive action of bisphosphonates has been considered the most effective in the disorders characterized by an excessive bone resorption. Zoledronate is superior to both clodronate or pamidronate in the treatment of MAH. Calcimimetic agents has been recently introduced to control hypercalcemia in selected cases of PHPT. They are used when surgery is not possible or patients do not meet surgical criteria. Malignancy- associate hypercalcemia is broadly divided into two categories: humoral MAH and osteolytic MAH. The first concerns the paraneoplastic release of humoral factors, mainly parathyroid hormone-related peptide (PTHrP). Recently a humanized monoclonal antibody against human PTHrP has been generated and is still under evaluation. The receptor activator of nuclear factor-κ ligand (RANKL) has a critical role in the etiology of malignancy skeletal complications. The fully humanized anti-RANKL antibody (denosumab) would seem to be even more effective than bisphosphonates to suppress bone resorption, as shown in preliminary results .
Keywords: Hypercalcemia, hyperparathyroidism, bisphosphonates, RANKL, PTHrP, parathyroidectomy, Zoledronate, denosumab, loop diuretics, concomitant natriuretic
Medicinal Chemistry
Title:Treatment of Chronic Hypercalcemia
Volume: 8 Issue: 4
Author(s): Valentina Camozzi, Giovanni Luisetto, Stefano M.M. Basso, Piero Cappelletti, Renato Tozzoli and Franco Lumachi
Affiliation:
Keywords: Hypercalcemia, hyperparathyroidism, bisphosphonates, RANKL, PTHrP, parathyroidectomy, Zoledronate, denosumab, loop diuretics, concomitant natriuretic
Abstract: Hypercalcemia is a relatively frequent alteration, mostly associated to primary hyperparathyroidism (PHPT) and malignancy-associated hypercalcemia (MAH). Treatment first includes rehydration and loop diuretics, as general measures. Bisphosphonates are considered the drugs of choice due to their long-term management. Calcitonin is preferable in the short-term control of severe hypercalcemia. The antireabsorptive action of bisphosphonates has been considered the most effective in the disorders characterized by an excessive bone resorption. Zoledronate is superior to both clodronate or pamidronate in the treatment of MAH. Calcimimetic agents has been recently introduced to control hypercalcemia in selected cases of PHPT. They are used when surgery is not possible or patients do not meet surgical criteria. Malignancy- associate hypercalcemia is broadly divided into two categories: humoral MAH and osteolytic MAH. The first concerns the paraneoplastic release of humoral factors, mainly parathyroid hormone-related peptide (PTHrP). Recently a humanized monoclonal antibody against human PTHrP has been generated and is still under evaluation. The receptor activator of nuclear factor-κ ligand (RANKL) has a critical role in the etiology of malignancy skeletal complications. The fully humanized anti-RANKL antibody (denosumab) would seem to be even more effective than bisphosphonates to suppress bone resorption, as shown in preliminary results .
Export Options
About this article
Cite this article as:
Camozzi Valentina, Luisetto Giovanni, M.M. Basso Stefano, Cappelletti Piero, Tozzoli Renato and Lumachi Franco, Treatment of Chronic Hypercalcemia, Medicinal Chemistry 2012; 8 (4) . https://dx.doi.org/10.2174/157340612801216355
DOI https://dx.doi.org/10.2174/157340612801216355 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naturally Plant-Derived Compounds: Role in Bone Anabolism
Current Molecular Pharmacology Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy A Clinician’s Guide to Monoamine Oxidase Inhibitors
Current Psychiatry Reviews Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Advanced Techniques for Penetration Enhancement in Transdermal Drug Delivery System
Current Drug Delivery Mutual Modulation of Femarelle and Vitamin D Analog Activities in Human Derived Female Cultured Osteoblasts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Delivery Systems Based on Titania Nanotubes and Active Agents for Enhanced Osseointegration of Bone Implants
Current Medicinal Chemistry The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
Current Pharmaceutical Design Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Controlled Drug Delivery Using Microdevices
Current Pharmaceutical Biotechnology Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Vitamin D and Cystic Fibrosis Lung Disease
Mini-Reviews in Medicinal Chemistry Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Current Topics in Medicinal Chemistry Chitosan Formulations as Carriers for Therapeutic Proteins
Current Drug Discovery Technologies Roles of Renal Proximal Tubule Transport in the Pathogenesis of Hypertension
Current Hypertension Reviews Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Structure, Pharmacology and Therapeutic Prospects of Family C G-Protein Coupled Receptors
Current Drug Targets Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in Osteosarcoma Treatment
Current Pharmaceutical Design The Innate Immunity: Roles for New Antifungal and Antibacterial Peptides Secreted by Chromaffin Granules from the Adrenal Medulla
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents